FDA 483 - Dedicated Phase I, Inc. - March 16, 2012

During an inspection, Dedicated Phase I, Inc. was cited for failing to conduct an investigation in accordance with the signed statement of investigator and investigational plan. Specifically, a required blood sample was not taken from a subject during a clinical trial. This indicates a deviation from protocol in a clinical research setting.